Mechanisms and management of diuretic resistance in congestive heart failure

Postgraduate Medical Journal

Volumn 79, Issue 931, 2003, Pages 268-271

  De Bruyne, L K M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BENDROFLUMETHIAZIDE; BUMETANIDE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; METOLAZONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

BOLUS INJECTION; CELL HYPERPLASIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DEHYDRATION; DIET RESTRICTION; DIURESIS; DIURETIC ACTIVITY; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; EPITHELIUM CELL; HEARING LOSS; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY DISEASE; KIDNEY FAILURE; LONG TERM CARE; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PATIENT COMPLIANCE; REVIEW; SODIUM INTAKE; SODIUM RETENTION; SURVIVAL; TINNITUS; TREATMENT OUTCOME;

EID: 0038648551     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.931.268     Document Type: Review

References (31)

1. Packer M, Cohn JN, Abraham WT. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A-38.
2. Wilcox CS. Diuretics. In: Brenner BM, Rector FC, eds. The kidney. Philadelphia: WB Saunders, 1996: 2299-330.
3. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8.
4. Schrier MW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
5. Packer M. Pathophysiology of chronic heart failure. Lancet 1992;340:88-92.
6. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995;57:601-9.
7. Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol 1999;19:581-97.
8. Koissling B, Stanton BA. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol 1988;255:F1256-68.
9. Stanton BA, Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Physiol 1998;255:F1269-75.
10. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989;36:682-9.
11. Kirchner KA, Martin CJ, Bower JD. Prostaglandin E2 but not 12 restores furosemide response in indomethacin-treated rats. Am J Physiol 1986;250:F980-5.
12. Feenstra J, Heerdinck ER, Grobbee DE, et al. Association of nonsteroidal anti- inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch Intern Med 2002;162:262-70.
13. Kuchor DL, O'Rourke MF. High dose furosemide in refractory cardiac failure. Eur Heart J 1985;6:954-8.
14. Gerlag PGG, van Meijel JJM. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med 1988;148:286-91.
15. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther 1980;28:182-6.
16. Brater DC, Day B, Burdette A, et al. Bumetanide and furosemide in heart failure. Kidney Int 1984;22:183-9.
17. Abrams J. Intramuscular bumetanide and furosemide in congestive heart failure. J Clin Pharmacol 1981;21:673-9.
18. Sagar S, Sharma BK, Sharma PL, et al. A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states. Int J Clin Pharmacol Ther Toxicol 1984;22:473-8.
19. Vasko MR, Brown-Cartwright D, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985;102:314-18.
20. Raftery EB. Hemodynamic effects of diuretics in heart failure. Br Heart J 1994;72:44.
21. Ryback LP. Ototoxicity of loop diuretics. Otolaryngol Clin North Am 1993;26:829-44.
22. Lahav M, Regev A, Ra'anani P, et al. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992;102:725-31.
23. van Meijel JJ, Smits P, Dormans T, et al. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med 1994;235:329-34.
24. Dormans TPJ, van Meijel JJM, Gerlag PGG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28:376-82.
25. Ferguson JA, Sundblad KJ, Becker PK, et al. Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther 1997;62:203-8.
26. van Vliet AA, Donker AJM, Nauta JJP, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:21A-8.
27. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
28. Kiyingi A, Field MJ, Pawsey CC, et al. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990;335:29-31.
29. Channer KS, McLean KA, Lawson-Matthew P, et al. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994;71:146-50.
30. Dormans TPJ, Gerlag PGG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 1996;17:1867-74.
31. Fliser D, Schröter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994;46:482-8.